Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Liquidia (Nasdaq:LQDA) announced that CEO Dr. Roger Jeffs and COO/CFO Michael Kaseta will discuss the company’s business in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 12:45 p.m. ET. The live webcast and a 30-day replay will be available on the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – LQDA
In the May 27 session, LQDA gained 3.21%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Earnings results | Positive | +25.6% | Strong Q1 2026 results from YUTREPIA with meaningful profitability. |
| May 06 | Investor conferences | Neutral | +5.0% | Participation in May 2026 investor conferences with senior management updates. |
| May 04 | Earnings date notice | Neutral | +0.9% | Announcement of timing and webcast for Q1 2026 results. |
| Apr 07 | Investor conferences | Neutral | -0.8% | April 2026 investor conferences with one-on-one meetings and webcast. |
| Mar 05 | Earnings results | Neutral | +0.4% | Full-year 2025 results highlighting YUTREPIA sales and mixed profitability. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings and conference announcements have generally seen price reactions that align with the informational or positive tone of the news.
Over the last few months, Liquidia reported strong financial results driven by YUTREPIA, including Q1 2026 net product sales of $129.9M and net income of $52.9M, following 2025 YUTREPIA product sales of $148.3M. The company has been active on the conference circuit, regularly hosting webcasts and fireside chats with management. This Jefferies Global Healthcare Conference appearance continues that pattern of frequent investor engagement alongside growing commercial traction and ongoing clinical studies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company’s business in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45 p.m. ET.
Access to this event will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the company’s website for at least 30 days.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® technology. PRINT enabled the development of YUTREPIA® (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
media@liquidia.com
